This product is a CXCL13 encoding oncolytic vaccinia virus, which is based on VACV-WR with E3L and K3L double deleted.Protein E3 plays a role in the inhibition of multiple cellular antiviral responses activated by dsRNA, such as inhibition of PKR activation, apoptosis, and IFN-mediated antiviral activities. Protein K3 acts as a pseudosubstrate for EIF2AK2/PKR kinase. Inhibits therefore eIF-2-alpha phosphorylation by host EIF2AK2/PKR kinase and prevents protein synthesis shutoff.The double deletion of E3L and K3L with oncolytic-rendered modifications could enhance an immune response to a poxvirus vaccine.This product can be used in oncolytic virotherapy research and vaccinie application.
Specifications
Family
Poxviridae
Species
Vaccinia virus
Serotype
Western Reserve
Backbone
VACV-WR (ΔE3L,ΔK3L)
Backbone Background
VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
B lymphocyte chemoattractant, independently cloned and named Angie, is an antimicrobial peptide and CXC chemokine strongly expressed in the follicles of the spleen, lymph nodes, and Peyer's patches. It preferentially promotes the migration of B lymphocytes (compared to T cells and macrophages), apparently by stimulating calcium influx into, and chemotaxis of, cells expressing Burkitt's lymphoma receptor 1 (BLR-1). It may therefore function in the homing of B lymphocytes to follicles.
Customer Reviews and Q&As
There are currently no customer reviews or questions for CXCL13-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L,ΔK3L), pSE-(CXCL13) (CyOV-0183WQ). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.
Datasheet